21st January 2021
Robert Lavine
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
21st January 2021
Robert Lavine
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
20th January 2021
Robert Lavine
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
20th January 2021
Robert Lavine
The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.
18th January 2021
Thierry Heles
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
28th December 2020
Robert Lavine
The chemical analysis device developer has added $20m to an initial public offering following $70m in funding from investors including Utec.
27th December 2020
Thierry Heles
Bar-Ilan University’s textile developer Sonovia has completed an $18.5m initial public offering on the Tel Aviv Stock Exchange.
23rd December 2020
Robert Lavine
UTokyo Innovation Platform has scored an exit as the online investment platform developer went public on the Tokyo Stock Exchange.
17th December 2020
Robert Lavine
The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.
14th December 2020
Robert Lavine
Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.